STF-logo-1

We use cookies to provide you a better experience. By continuing to use this website, you consent to the use of cookies in accordance with our Cookie Policy.

Equity Capital Markets

Stifel ECM delivers a full suite of equity and equity linked products including IPOs, Follow-ons, Converts and SPACs across all of our focus sectors

Equity Capital Markets Group

Industry-Leading Full-Service Equity Capital Markets Group

The Equity Capital Markets Group (ECM) is responsible for originating and executing public and private equity and equity linked offerings as well as SPACs. In 2021, the ECM group managed over 265 equity and equity-linked transactions, including executing 76 IPOs, raising more than $108B. In addition, the ECM team has a leading SPAC business, advising in 2021 on more than 45 transactions within all phases of the Special Purpose Acquisition Company (SPAC) lifecycle, including IPOs, PIPEs, and de-SPAC engagements. The Stifel equity platform brings differentiated institutional access and retail distribution in the US and Internationally.

Stifel is the Leading IPO Bookrunner Among All Middle-Market or Specialist Firms

Learn More

Notable Transactions

Image
$ 175,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2025

Image
$ 202,000,000
Joint Bookrunning Manager

Initial Public Offering

Medtech

Mar 2025

Image
C$ 17,400,000
Sole Bookrunner

Follow-on Offering

Metals & Mining

Feb 2025

Image
C$ 39,005,077
Joint Bookrunner

Private Placement

Metals & Mining

Feb 2025

Image
A$ 80,000,000
Joint Lead Arranger & Joint Bookrunner

Follow-on Offering

Energy & Natural Resources

Feb 2025

Image
$ 384,000,000
Joint Bookrunner

Initial Public Offering

Building Products

Feb 2025

Image
$ 219,200,000
Joint Bookrunner

Initial Public Offering

Biopharma

Feb 2025

Image
$ 150,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Feb 2025

Image
$ 230,000,000
Left Bookrunner

Follow-on Offering

Energy & Natural Resources

Feb 2025

Image
$ 75,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Jan 2025

Image
$ 50,000,000
Joint Bookrunner

Registered Direct

Biopharma

Dec 2024

Image
$ 257,600,000
Joint Bookrunner

Follow-on Offering

Biopharma

Dec 2024

Image
$ 624,800,000
Joint Bookrunner

Initial Public Offering

Software

Dec 2024

Image
$ 402,500,000
Joint Bookrunner

Follow-on Offering

Biopharma

Dec 2024

Image
$ 115,000,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Aerospace, Defense & Government Services

Dec 2024

Image
$ 196,956,533
Joint Bookrunner

Follow-on Offering

Energy & Natural Resources

Nov 2024

Image
$ 152,500,000
Joint Bookrunner

Follow-on Offering

Aerospace, Defense & Government Services

Nov 2024

Image
$ 60,000,000
Joint Bookrunner & Joint Placement Agent

Registered Direct & PIPE

Biopharma

Nov 2024

Image
$ 172,499,859
Joint Bookrunner

Follow-on Offering

Aerospace, Defense & Government Services

Oct 2024

Image
$ 94,500,000
Joint Bookrunner

Follow-on Offering

Real Estate

Sep 2024

Image
$ 517,500,000
Joint Bookrunner

Follow-on Offering

Industrial & Environmental Services

Sep 2024

Image
$ 575,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Sep 2024

Image
$ 187,680,000
Joint Bookrunner

Initial Public Offering

Biopharma

Sep 2024

Image
$ 362,250,000
Joint Bookrunner

Initial Public Offering

Biopharma

Sep 2024

Image
$ 200,536,320
Joint Placement Agent

PIPE

Biopharma

Sep 2024

Image
$ 258,750,000
Joint Bookrunning Manager

Follow-on Offering

Biopharma

Sep 2024

Image
$ 200,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Sep 2024

Image
$ 152,173,925
Joint Bookrunner

Follow-on Offering

Energy & Natural Resources

Sep 2024

Image
$ 137,000,000

Follow-on Offering

Energy & Natural Resources

Sep 2024

Image
$ 220,000,000
Sole Bookrunner

Initial Public Offering

Business Services

Sep 2024

Image
$ 96,000,000
Joint Bookrunner

Follow-on Offering

Aerospace, Defense & Government Services

Sep 2024

Image
$ 258,750,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Aug 2024

Image
$ 130,000,000
Joint Bookrunner

Registered Direct

Biopharma

Aug 2024

Image
$ 33,900,000
Sole Bookrunner

Follow-on Offering

Biopharma

Aug 2024

Image
$ 100,000,000
Lead Financial Advisor

Convertible Notes & Senior Secured Term Loan

Medtech

Aug 2024

Image
$ 231,000,000
Joint Bookrunner

Follow-on Offering

Energy & Natural Resources

Jul 2024

Image
$ 174,400,000
Joint Bookrunner

Initial Public Offering

Biopharma

Jun 2024

Image
$ 75,000,000
Joint Bookrunning Manager

Initial Public Offering

Industrial Technology

Jun 2024

Image
$ 155,250,000
Joint Bookrunner

Initial Public Offering

Internet & Digital Media

Jun 2024

Image
$ 60,000,000
Joint Bookrunner

Registered Direct

Biopharma

May 2024

Image
$ 374,325,000
Joint Bookrunner

Follow-on Offering

Biopharma

May 2024

Image
€ 40,300,000
Joint Global Coordinator / Joint Bookrunner

Block Trade

Diversified Industries

May 2024

Image
$ 150,000,000
Joint Bookrunner

Follow-on Offering

Aerospace, Defense & Government Services

May 2024

Image
$ 236,525,000
Left Bookrunner

Initial Public Offering

Transportation & Logistics

May 2024

Image
$ 75,000,000
Sole Bookrunner

Registered Direct

Biopharma

May 2024

Image
$ 120,000,000
Joint Bookrunner

Follow-on Offering

Engineering & Construction, and Infrastructure

Apr 2024

Image
$ 280,000,000
Joint Placement Agent

PIPE

Biopharma

Apr 2024

Image
$ 275,000,000
Co-Manager

Follow-on Offering

Metals & Mining

Apr 2024

Image
$ 9,844,961
Sole Placement Agent

Registered Direct

Aerospace, Defense & Government Services

Apr 2024

Image
$ 201,250,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Apr 2024

Image
$ 110,000,000
Joint Bookrunner

Initial Public Offering

Biopharma

Apr 2024

Image
C$ 23,011,788
Joint Bookrunner

Follow-on Offering

Healthcare & Special Situations

Mar 2024

Image
$ 240,100,310
Joint Bookrunner

Registered Direct

Biopharma

Mar 2024

Image
$ 150,000,000
Joint Bookrunner

Registered Direct

Biopharma

Mar 2024

Image
$ 180,000,000
Joint Placement Agent

PIPE

Biopharma

Mar 2024

Image
$ 125,000,025
Joint Bookrunner

Follow-on Offering

Electronics & Industrial Technology

Mar 2024

Image
$ 482,999,902
Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2024

Image
$ 140,000,000
Joint Bookrunner

Follow-on Offering

Biopharma

Mar 2024

Image
$ 632,540,250
Joint Bookrunner

Follow-on Offering

Biopharma

Feb 2024

Image
$ 160,125,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Feb 2024

Image
$ 57,800,000
Joint Bookrunner

Follow-on Offering

Energy & Natural Resources

Feb 2024

Image
$ 172,800,000
Joint Bookrunner

Follow-on Offering

Real Estate

Jan 2024

Image
$ 345,144,000
Joint Bookrunner

Follow-on Offering

Biopharma

Jan 2024

Image
C$ 25,000,000
Joint Bookrunner

Private Placement

Technology

Dec 2023

Image
$ 230,000,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Dec 2023

Image
$ 20,300,000
Left Bookrunner

Registered Direct

HealthTech

Dec 2023

Image
$ 180,000,000
Joint Placement Agent

PIPE

Biopharma

Dec 2023

Image
$ 175,000,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Electronics & Industrial Technology

Dec 2023

Image
$ 300,000,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Biopharma

Nov 2023

Image
$ 111,536,216
Joint Bookrunner

Initial Public Offering

Biopharma

Nov 2023

Image
$ 190,000,000
Left Bookrunner

Initial Public Offering

Energy & Natural Resources

Oct 2023

Image
$ 150,150,000
Joint Bookrunner

Confidentially Marketed Follow-on Offering

Medtech

Oct 2023

Image
$ 4,483,000,000
Financial Advisor

Has Completed a Spin-off

Capital Goods

Oct 2023

Image
$ 100,000,000
Joint Bookrunner

Registered Direct

Biopharma

Oct 2023

Image
$ 115,000,000
Joint Bookrunner

Confidentially marketed Follow-on Offering

Biopharma

Sep 2023

Currency volume represents full credit to each underwriter. All transaction announcements appear as a matter of record only. Stifel collectively refers to Stifel, Nicolaus & Company, Incorporated and other affiliated broker-dealer subsidiaries of Stifel Financial Corp.

Team

Team

Seth Rubin

Head of Global Equity Capital Markets

San Francisco

Team

Cullen Lee

Managing Director, Head of Technology ECM

Team

Christophe Alleman

Managing Director

Paris

Team

Brian Anderson

Managing Director

Bethesda

Team

Bill Bunting

Managing Director, Equity Private Placements

San Francisco

Team

Lewis Chia

Managing Director

San Francisco

Team

Ken Clausman

Managing Director

New York

Team

Daniel J. Covatta

Co-Head of U.S. Syndicate

Baltimore

Team

Alysa Craig

Managing Director, Head of SPAC Banking

New York

Team

Craig DeDomenico

Managing Director

New York

Team

Nicholas Oust

Managing Director

San Francisco

Team

Rosemary Teixeira

Managing Director, Head of ECM, Stifel Canada

Toronto

Team

Paul Lequeux

Director

London

Team

Jean De Pracomtal

Director

Paris

Team

Mark White

Director, Equity Capital Markets & Syndicate

Baltimore

About Us Stifel Institutional Stifel Sustainability Practices
Capabilities Investment Banking Equities Equity Research Fixed Income Capital Markets Public Finance Serving Business Leaders
Global Coverage Overview Europe & UK Canada Asia Israel Latin America
Insights & Perspectives Thought Leadership Stifel in the News Stifel Investor Insights Stifel IRIS
Careers Experienced Professionals Campus Careers & Entry Level Opportunities
Disclosures Important Disclosures Your Privacy Form CRS FINRA BrokerCheck
Connect with Stifel Client Access Stifel Wealth Tracker
STF-footer-logo

In the United States, this site is published in the United States for U.S. residents only. The information on this web site is not an offer to sell or a solicitation of an offer to buy any security, nor shall any such security be offered or sold to any person in any jurisdiction in which such offer, solicitation, purchase, or sale may not lawfully be made. Stifel Financial Advisors may only conduct business with residents of the states in which they are properly registered. References to Stifel herein may apply to parent company Stifel Financial Corp. or any of its wholly owned subsidiaries, including Stifel, Nicolaus & Company, Incorporated, Member NYSE, FINRA, and SIPC. Stifel Nicolaus Europe Limited is authorised and regulated by the Financial Conduct Authority.

Copyright © 2025 Stifel Financial Corp. All rights reserved.